GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioNTech SE (BSP:B1NT34) » Definitions » Net Interest Income

BioNTech SE (BSP:B1NT34) Net Interest Income : R$2,225 Mil (TTM As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is BioNTech SE Net Interest Income?

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors. BioNTech SE's net interest income for the three months ended in Dec. 2023 was R$625 Mil. Its net interest income for the trailing twelve months (TTM) ended in Dec. 2023 was R$2,225 Mil.

BioNTech SE Net Interest Income Historical Data

The historical data trend for BioNTech SE's Net Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioNTech SE Net Interest Income Chart

BioNTech SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Interest Income
Get a 7-Day Free Trial -0.91 -21.91 -164.86 164.47 1,868.55

BioNTech SE Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Interest Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 203.93 328.47 794.58 477.00 625.17

BioNTech SE Net Interest Income Calculation

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors.

Net Interest Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was R$2,225 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioNTech SE Net Interest Income Related Terms

Thank you for viewing the detailed overview of BioNTech SE's Net Interest Income provided by GuruFocus.com. Please click on the following links to see related term pages.

BioNTech SE (BSP:B1NT34) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioNTech SE (BSP:B1NT34) » Definitions » Net Interest Income
Comparable Companies
BGNE ALNY MRNA BMRN RPRX LEGN INCY UTHR SRPT TECH OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 HKSE:02269 XBRU:ARGX SZSE:300122 OCSE:GMAB
Traded in Other Exchanges
BNTX:USA BNTX:Mexico 0A3M:UK 22UA:Germany BNTX:Austria
Address
An der Goldgrube 12, Mainz, RP, DEU, D-55131
Website
https://www.biontech.de
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. COVID-19 vaccine Comirnaty is its first commercialized product.

BioNTech SE (BSP:B1NT34) Headlines

No Headlines